| #Neurologytour "Innovation In Neurological Disorders Therapies And Neuroprotection" |
26 ottobre 2017 |
11.00-13.00 |
| Acetylsalicylic Acid, 120 Years Later |
25 ottobre 2017 |
14.30-16.30 |
| Advanced Therapies And Medical Devices Combination With Innovative Therapies |
27 ottobre 2017 |
16.00-18.00 |
| Advances In Multiple Sclerosis |
26 ottobre 2017 |
9.30-10.30 |
| Appropriate Use Of Opiates And Risk Of Abuse Liability |
27 ottobre 2017 |
10.30-11.30 |
| Cardiovascular Risk Prevention And The Chronic Patient |
28 ottobre 2017 |
10.30-12.00 |
| Clinical And Experimental Aspects Of Novel Antidiabetic Therapies . From The Gut And The Kidney Towards The Cardiovascular System : The Last Ten Years Of The Antidiabetic Drugs. |
26 ottobre 2017 |
14.00-16.00 |
| Clinical Perspectives Of Nutraceuticals |
26 ottobre 2017 |
14.00-16.00 |
| Clinical Pharmacology Of Cardio-Oncology |
27 ottobre 2017 |
10.30-12.30 |
| Current Topics And Perspectives Of Precision Therapy In Oncology |
26 ottobre 2017 |
11.00-13.00 |
| Effectiveness And Safety Of Direct Oral Anticoagulants In Clinical Practice: Comparison Of Viewpoints |
26 ottobre 2017 |
17.00-18.00 |
| Efficacy, Safety And Effectiveness Of Isglt2 (Sodium Glucos E Co-Transporter Type 2 Inhibitor) : Current And Future Role |
27 ottobre 2017 |
11.30-12.30 |
| Emerging Epigenetic Strategies In Pharmacological Therapy |
26 ottobre 2017 |
17.00-19.00 |
| Environmental Enrichment And Brain Repair: The Therapeutic Effects O Cognitive Training In Neurological Diseases |
27 ottobre 2017 |
8.30-9.30 |
| Evolution Of The Therapeutic Approach To The Hiv Infection: Not Only "Viral Load" |
27 ottobre 2017 |
10.30-11.30 |
| From Big Data To Smart Data: Aims, Tools And Knowledge In The Real World Evidence |
27 ottobre 2017 |
9.30 - 11.30 |
| From Psychological Stress To Neurodegeneration: Novel Pharmacological Targets And Neuroprotective Approaches |
27 ottobre 2017 |
8.30-10.30 |
| From Urate Deposition To Cv Risk: The Role Of The Xanthineoxidase Modulation |
26 ottobre 2017 |
14.00-15.00 |
| Heart Failure: Different Approaches To The Same Problem |
26 ottobre 2017 |
8.30-10.30 |
| Hepatitis C Therapy: Pharmacokinetics, Pharmacodynamics And Clinical Outcomes |
27 ottobre 2017 |
15.30-16.30 |
| Innovation Of Mechanism Of Action In Oncology |
26 ottobre 2017 |
15.00-16.00 |
| Neurofunctional And Metabolic Alterations Induced By Maladaptive Eating And Stress: Serching For Novel Pharmacological Targets |
25 ottobre 2017 |
14.30-16.30 |
| Neuroprotection And Neuroenhancement: Lessons Learned From Ocular Disorders |
27 ottobre 2017 |
14.30-16.00 |
| New Approaches To The Inflammation Pharmacology |
26 ottobre 2017 |
10.30-12.30 |
| New Directions In Orphan Drugs For Rare Diseases: From Clinical Trials To Regulatory Paths |
27 ottobre 2017 |
8.30-11.00 |
| New Insights On Osteoporotic Drugs And Future Therapeutic Prospectives |
28 ottobre 2017 |
11.00-12.00 |
| Novel Biological And Pharmacological Aspects In The Brain Tumors |
27 ottobre 2017 |
8.30-9.30 |
| Nutraceutical Compounds: Current And Future Perspectives |
26 ottobre 2017 |
11.00-13.00 |
| Old And New Fields For Ion Channel Pharmacology: Still Surfing On The Crest Of A Wave |
28 ottobre 2017 |
10.30-12.00 |
| On The Bright And The Dark Side Of Amyloid Beta: Looking Over Alzheimer's Disease |
26 ottobre 2017 |
14.00-16.00 |
| Pediatric Pharmacology And The New European Union (Eu) Clinical Trial Regulation: Perspectives And Opportunities |
25 ottobre 2017 |
14.30-16.30 |
| Pharmacological Control Of Tumor Ne Crosis Factor (Tnf) In Immunomediated Inflammatory Diseases (Imid): The Value Of Adalimumab |
26 ottobre 2017 |
14.00-15.00 |
| Pharmacological Modulation Of Novel Molecular Systems In The Management Of Patients With Complex Pathologies |
27 ottobre 2017 |
14.30-15.30 |
| Pharmacological Strategies Defending The Heart From Fat Attack: A New Role For Direct-Acting Oral Anticoagulants Doac? - The Epicardial Adipose Tissue (Epa), A Sick (Visceral) Fat Embracing The Heart |
28 ottobre 2017 |
9.00-10.30 |
| Phenotyping Chronic Obstructive Pulmonary Disease (Copd): Pharmacological And Toxicological Implications |
26 ottobre 2017 |
8.30-10.30 |
| Precision Medicine And Pharmacological Treatment Of Psychiatric Disorders |
27 ottobre 2017 |
14.30-16.00 |
| Psychiatric Vulnerability Of The Developing Brain: Suggestions From Animal Models And Critical Time Windows For Pharmacological Intervention |
26 ottobre 2017 |
17.00-19.00 |
| Rare Diseases Therapy: From Clinical Needs To Therapeutic Solutions |
27 ottobre 2017 |
11.00-12.00 |
| Stress-Induced Psychopathologies: Molecular Markers Of Vulnerability And Novel Pharmacological Targets |
26 ottobre 2017 |
8.30-10.30 |
| Study, Development And Rationale Use Of Immunopharmacological Agents |
26 ottobre 2017 |
17.00-18.30 |
| Th2 Pathway In Immunological Diseases: New Frontiers For Treatment Of Atopic Disease |
27 ottobre 2017 |
14.30-16.00 |
| The Clinical Evolution Of Pharmacology |
26 ottobre 2017 |
17.00-18.30 |
| The Endocannabinoid System And Autism Spectrum Disorders |
27 ottobre 2017 |
16.30-18.30 |
| The Future Of Pharmacovigilance And The Role Of Risk Communication |
26 ottobre 2017 |
8.30-10.30 |
| The Pharmacologist And The Microbiota Challenge |
27 ottobre 2017 |
10.30-12.30 |
| The Purinergic System: A New Promising Target For Human Diseases |
28 ottobre 2017 |
9.00-11.00 |
| Translational Research Openings For The Cure Of Amyotrophic Lateral Sclerosis (Als) |
27 ottobre 2017 |
16.00-18.00 |
| Translational Strategy For Assessing New Mechanisms For The Development Of Innovative Therapeutic Approach In Psychiatric Disorders |
26 ottobre 2017 |
8.30-10.30 |
| Type 2 Diabetes: Glycemic Control And Innovation Therapy |
26 ottobre 2017 |
12.30-13.00 |
